Key Takeaways Focus on product optimization and balance sheet strength aims to enhance margins and drive acquisition-fueled growth in high-margin segments. Emphasis on advanced technologies like robotic surgery and gene sequencing aligns with market trends, potentially boosting future revenue and competitive margins.Read more
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis. It offers products and solutions, including analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical services; and in the areas of microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics, as well as in the food industry. This segment also provides training programs for its customers. The Medtech segment provides medical device products for surgery, orthopaedics, critical care, endoscopy, wound care, healthcare IT, ophthalmology, home adaptation, and technical aids, as well as surgical procedures, welfare technology, and assistive devices for the elderly and disabled. It operates in Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, Germany, Poland, Austria, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
